U.S. Communications Stock News

NYSE:IVZ
NYSE:IVZCapital Markets

Is Invesco (IVZ) Stock Pricing In Too Much Optimism After Its Strong Three Year Run

If you are wondering whether Invesco's current share price really reflects its fundamentals, you are not alone. This article focuses squarely on what you might be paying for and what you are getting. Invesco's stock closed at US$26.26, with returns of 57.2% over 1 year and 68.9% over 3 years, even as the last 7 days, 30 days and year to date show declines of 0.8%, 4.7% and 2.5% respectively. Recent coverage around Invesco has focused on its position in asset management and how investors view...
NYSE:IMAX
NYSE:IMAXEntertainment

IMAX Record Box Office And Expansion Raise Questions For Investors

IMAX (NYSE:IMAX) reports a record 2025 global box office of US$1.28b. The company cites year on year growth in both revenue and operating margin for 2025. Local language films and international markets are highlighted as key content and growth drivers. IMAX expands its footprint in underpenetrated markets, including Japan, Australia, France, and Germany, with more system installations. A new partnership with Apple TV will bring live Formula 1 races into IMAX theaters. For investors watching...
NYSE:AOS
NYSE:AOSBuilding

Do A. O. Smith’s Commercial Pivot and Control Acquisitions Reshape Its Core Investment Narrative (AOS)?

In late February 2026, analysts at Goldman Sachs and Stifel updated their research on A. O. Smith, highlighting the company’s improving profitability, resilient commercial water heater and boiler performance, and mixed quarterly results alongside macro headwinds and housing-related pressures. CEO Steve Shafer’s emphasis on record EPS in 2025 and the portfolio-expanding acquisitions of Leonard Valve and Heat-Timer underscored a shift toward higher-growth, higher-margin opportunities in...
NYSE:PPL
NYSE:PPLElectric Utilities

Assessing PPL (PPL) Valuation After US$1b Offering Earnings Beat Dividend Hike And Upgraded Guidance

PPL (PPL) is in focus after completing a US$1b composite units offering and reporting fresh earnings, dividend, and guidance updates, giving investors several new data points to consider on the stock. See our latest analysis for PPL. PPL’s latest earnings, dividend increase, and US$1b composite units offering arrive after a period of steady gains, with an 11.02% year to date share price return and a 67.25% five year total shareholder return. This suggests momentum has been building rather...
NYSE:TKR
NYSE:TKRMachinery

The Bull Case For Timken (TKR) Could Change Following New Buyback And Humanoid Robotics M&A Focus

The Timken Company recently authorized a share repurchase program for up to 10,000,000 shares through February 28, 2031, while also signaling continued interest in mergers and acquisitions, including opportunities linked to humanoid robotics. By pairing a long-duration buyback plan with an active M&A agenda, Timken is emphasizing both capital return and portfolio expansion as key priorities. Next, we’ll examine how Timken’s long-term share repurchase authorization could reshape its existing...
NYSE:TWLO
NYSE:TWLOIT

Is Twilio (TWLO) Pricing Look Attractive After Mixed Multi Year Share Performance

If you are wondering whether Twilio shares are attractively priced or still carry too much risk, you are not alone. This article is designed to help you make sense of where the current valuation sits. Twilio last closed at US$120.96, with a 6.9% return over the past week, an 11.0% decline over the past month, and year to date and 1 year returns of a 12.6% decline and 0.9% respectively, alongside a 63.7% gain over 3 years and a 64.1% decline over 5 years. These mixed returns sit against a...
NYSE:ARX
NYSE:ARXInsurance

Accelerant Refreshes Legal And Investor Relations Leadership As Story Evolves

Accelerant Holdings (NYSE:ARX) appointed Cliff Jenks as General Counsel and Corporate Secretary, succeeding founding executive Nancy Hasley, who is retiring. The company also created a new Head of Investor Relations role, naming Ray Iardella to lead engagement with shareholders and the market. These leadership changes focus on legal governance and investor communications, two areas that are central to how the company presents itself to public markets. Accelerant Holdings, trading at around...
NYSE:SMA
NYSE:SMASpecialized REITs

Assessing SmartStop Self Storage REIT (SMA) Valuation After Recent Share Price Momentum

Why SmartStop Self Storage REIT is on investors’ radar today SmartStop Self Storage REIT (SMA) has drawn attention after recent share price moves, with the stock up around 7% over the past month and roughly 2% over the past 3 months. See our latest analysis for SmartStop Self Storage REIT. At a share price of US$33.35, SmartStop Self Storage REIT has a 1 day share price return of 1.06%. Its 30 day and year to date share price returns of 7.10% and 8.42% suggest momentum has been building...
NYSE:VSH
NYSE:VSHElectronic

What Vishay Intertechnology (VSH)'s New VOx619A Energy‑Efficient Optocouplers Mean For Shareholders

In February 2026, Vishay Intertechnology introduced its VOx619A phototransistor optocoupler series, featuring low 0.5 mA forward current, high linear current transfer ratio over temperature, and operation up to +125 °C across four isolation-focused package options for industrial, telecom, and consumer uses. The combination of higher temperature tolerance, more consistent signal transfer, and lower power consumption positions these optocouplers as a way to support more efficient,...
NasdaqGS:NTRA
NasdaqGS:NTRABiotechs

Natera (NTRA) Q4 Profit Sparks Questions Around Bullish Earnings Turnaround Narrative

Natera (NTRA) just closed out FY 2025 with fourth quarter revenue of US$665.5 million and basic EPS of US$0.34, alongside trailing twelve month revenue of about US$2.3 billion and a TTM basic EPS loss of US$1.52. The company has seen quarterly revenue move from US$476.1 million in Q4 2024 to US$665.5 million in Q4 2025, while quarterly basic EPS shifted from a loss of US$0.41 in Q4 2024 to EPS of US$0.34 in Q4 2025. This sets up a results season where investors are focused squarely on how...
NYSE:BKSY
NYSE:BKSYProfessional Services

BlackSky Technology (BKSY) Deepens Rocket Lab Ties and Grows Gen-3 Backlog Is Its Moat Emerging?

In February 2026, Rocket Lab USA announced a new multi-launch agreement with BlackSky Technology, adding four dedicated Electron missions to deploy BlackSky’s AI-enabled Gen-3 Earth observation satellites and bringing their total launches together to 17 since 2019. BlackSky also reported fourth-quarter 2025 results showing year-over-year revenue growth to US$35.21 million and a sharply reduced quarterly net loss to US$0.87 million, alongside fresh 2026 revenue guidance and sizeable new Gen-3...
NasdaqGS:AMZN
NasdaqGS:AMZNMultiline Retail

Reassessing Amazon.com (AMZN) After 121% Three Year Rally And Recent Share Price Pullback

If you are wondering whether Amazon.com is still a reasonable entry at around US$209.97, the key question is whether the current price reflects its underlying business value. After a 121.3% return over 3 years but a 13.6% decline over the past 30 days and a 7.3% decline year to date, some investors are reassessing both the growth potential and the level of risk they are taking on with Amazon.com. Recent news flow around Amazon.com has continued to focus on its role as a large e commerce and...
NYSE:ARW
NYSE:ARWElectronic

Arrow Electronics Taps NomAIzo To Push Deeper Into Edge To Cloud AI

eInfochips, a subsidiary of Arrow Electronics (NYSE:ARW), has launched NomAIzo, a suite of AI-focused platforms, frameworks, and services. NomAIzo is designed to help customers accelerate edge to enterprise AI adoption across use cases from devices to the cloud. The launch expands Arrow Electronics' presence in AI and high tech engineering services by broadening its edge to cloud offering. For you as an investor, NomAIzo ties directly into what Arrow Electronics already does across...
NasdaqGS:LAMR
NasdaqGS:LAMRSpecialized REITs

How Lamar’s Expanded Buyback and Dividend Plans Will Impact Lamar Advertising (LAMR) Investors

Lamar Advertising recently declared a past quarterly cash dividend of US$1.60 per share, payable on March 31, 2026, and extended its stock and debt repurchase programs, each authorizing up to US$250.00 million through September 30, 2027. These moves highlight management’s focus on returning capital to shareholders while signaling confidence in the company’s balance sheet and cash-generation capacity. Now we’ll examine how the extended stock repurchase authorization influences Lamar’s...
NasdaqGM:RLAY
NasdaqGM:RLAYBiotechs

Relay Therapeutics (RLAY) Losses Of US$276.5 Million Test Bullish Revenue Growth Narrative

Relay Therapeutics FY 2025 earnings: revenue modest, losses continue as investors focus on growth potential Relay Therapeutics (RLAY) has wrapped up FY 2025 with Q4 revenue of US$7 million, a basic EPS loss of US$0.32, and net income loss of US$54.89 million, keeping the story firmly in loss-making territory as the market weighs its growth profile. The company has seen quarterly revenue move between US$0 million and US$7.68 million over the past year, while basic EPS losses have ranged from...
NYSE:FERG
NYSE:FERGTrade Distributors

Does Ferguson’s 2026 Outlook and Capital Returns Shift the Bull Case For Ferguson (FERG)?

In late February 2026, Ferguson Enterprises Inc. reported past fourth-quarter sales of US$7,495 million and net income of US$389 million, alongside five‑month sales of US$12,833 million and net income of US$786 million, while also outlining low‑ to mid‑single‑digit net sales growth expectations for the 2026 calendar year. Along with these results, Ferguson continued to return cash to shareholders through US$248.45 million of share repurchases completing a multi‑year US$4.49 billion program...
NYSE:EXPD
NYSE:EXPDLogistics

Does Expeditors (EXPD) Prioritize Buybacks Over Operational Resilience Amid Softer Ocean Freight Trends?

In February 2026, Expeditors International of Washington reported fourth-quarter 2025 results showing revenue of US$2,855.95 million and net income of US$200.71 million, alongside authorizing a new US$3.00 billion share repurchase program and completing a long-running US$8.72 billion buyback. While full-year 2025 revenue and earnings per share grew modestly, weaker ocean freight performance and higher headcount weighed on quarterly profitability. We will now examine how softer ocean freight...
NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

Assessing Corvus Pharmaceuticals (CRVS) Valuation After New Soquelitinib Trial Plans And Atopic Dermatitis Data

Conference update and pipeline focus Corvus Pharmaceuticals (CRVS) has come into focus after its appearance at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, where management outlined fresh details on lead candidate soquelitinib across several immune related indications. The company highlighted plans for a phase III interim analysis in peripheral T cell lymphoma by year end 2026, new phase II studies in asthma and hidradenitis suppurativa, and early atopic dermatitis data...
NasdaqGS:CENT
NasdaqGS:CENTHousehold Products

Central Garden And Pet Weighs Revenue Pressure Against Buybacks And Board Shift

Central Garden & Pet reported a 6% year over year revenue decline in its latest quarter. The company expanded its share repurchase program, signaling an increased focus on buybacks. Central Garden & Pet also refreshed its board of directors with new appointments. Central Garden & Pet, traded as NasdaqGS:CENT, released results that showed weaker revenue and earnings alongside the slowest revenue growth among its household product peers. The stock last closed at $39.18 and is up 22.1% over...
NYSE:UHS
NYSE:UHSHealthcare

Is It Time To Reassess Universal Health Services (UHS) After Recent Share Price Weakness?

If you are wondering whether Universal Health Services is attractively priced or starting to look expensive, you are in the right place for a clear look at what the market might be implying about its value. The shares last closed at US$206.10, with returns of a 10.6% decline over 7 days, 1.5% over 30 days, a 6.3% decline year to date, 18.1% over 1 year, 64.2% over 3 years, and 61.1% over 5 years. This gives you a broad sense of how sentiment around the stock has shifted over time. Recent...
NasdaqGS:ON
NasdaqGS:ONSemiconductor

ON Semiconductor Resets Portfolio Toward Silicon Carbide And AI Power Growth

ON Semiconductor is sharpening its focus on higher margin areas, including silicon carbide products and AI data center power solutions. The company is reallocating capital toward projects it views as higher return and scaling back exposure to weaker end markets such as electric vehicles and smartphones. Management is emphasizing capital discipline and targeted investment as it reshapes the business mix of NasdaqGS:ON. For investors tracking NasdaqGS:ON, this reset comes with the stock...
NasdaqGS:CCB
NasdaqGS:CCBBanks

Why Coastal Financial (CCB) Is Down 11.3% After Revenue Miss Despite Loan And Deposit Growth

Coastal Financial recently reported a past-quarter update showing a 1.3% year-on-year revenue decline, missing analysts’ expectations by 16.6%, even as loans receivable grew 1.2% and deposits rose 4.3%. Management emphasized the potential of its Banking-as-a-Service platform, highlighting plans to expand product offerings and scale new and existing partnerships despite the disappointing revenue and net interest income performance. We’ll now examine how Coastal Financial’s revenue shortfall...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA)

Vera Therapeutics reported full-year 2025 results showing a net loss of US$299.62 million, while advancing atacicept with positive Phase 3 IgA nephropathy data and securing FDA priority review with a July 7, 2026 PDUFA date. Alongside filing a US$191.89 million Class A common stock shelf registration for an ESOP-related offering, the company highlighted that its cash, equivalents, marketable securities and debt facility availability are expected to fund operations through potential atacicept...
NasdaqCM:PLSE
NasdaqCM:PLSEMedical Equipment

Pulse Biosciences (PLSE) Is Down 12.6% After Wider Losses And New Funding Plans - Has The Bull Case Changed?

Pulse Biosciences, Inc. reported a full-year 2025 net loss of US$72.78 million, widening from US$53.59 million in 2024, and filed new universal and ESOP-related shelf registrations alongside a reconfigured at-the-market common stock offering. At the same time, FDA approval to begin a paroxysmal atrial fibrillation study with the nPulse Cardiac Catheter System and a planned thyroid cancer collaboration with The University of Texas MD Anderson Cancer Center underscore how the company is...